Skip to main content
search
Entrevista “100 años de la Insulina: La Innovación en Diabetes”
DiabetesDiabetes - VideocápsulasInyectable Insulinas MGVideocápsulas

Entrevista “100 años de la Insulina: La Innovación en Diabetes”

By julio 23, 2021abril 13th, 2022No Comments

Estimado Dr. (a) le invitamos a ver la siguiente Entrevista: “100 años de la Insulina: La Innovación en Diabetes”.

Por el Dr. Valentín Sánchez Pedraza. Especialista en Endocrinología y Maestría en Ciencias de la Salud. Hospital General de México. Cédula 4795309. Y el Dr. Juan Antonio Peralta Calcáneo. Especialista en Endocrinología y Medicina Interna. Jefe de Endocrinología del Hospital. General de México. Cédula 6384281.

 

 

Referencias:

  1. Mazur A. Why were “starvation diets” promoted for diabetes in the pre-insulin period? Nutr J. 2011 Mar 11;10:23.
  2. https://www.theglobeandmail.com/news/national/canada-150/insulin-the-canadian-discovery-that-has-saved-millions-of-lives/article35537847/ 
  3. Diabetes Control and Complications Trial Research Group, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. 
  4. Learman I. Barreras que dificultan la aplicación temprana de insulina en el paciente con diabetes tipo 2. Rev ALAD. VOL.XVII–No2-Año 2009. 66-68. 
  5. Turner RC, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 Jun 2;281(21):2005-12. 
  6. Khunti K, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013 Nov;36(11):3411-7.
  7. Hirsch IB, et al. The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocr Rev. 2020 Oct 1;41(5):733-755.
  8. Vecchio I, et al. The Discovery of Insulin: An Important Milestone in the History of Medicine. Front Endocrinol (Lausanne) 2018 Oct 23;9:613. 
  9. Goldberg EF, Barreto T. Concepts and clinical use of ultra-long basal insulin. Diabetol Metab Syndr. 2016 Jan 6;8:2.
  10. Pettus J, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016 Sep;32(6):478-96.
  11. Tibaldi J, Rakel RE. Why, when and how to initiate insulin therapy in patients with type 2 diabetes. Int J Clin Pract 2007 Apr;61(4):633-44.
  12. Choe C, Edelman S. New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc 2007 Apr;99(4):357-60, 363-7.
  13. Mathieu C, et al. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol. 2017 Jul;13(7):385-399. 
  14. Jonassen IB, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012 Aug;29(8):2104-14. 
  15. Rodbard HW, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med 013 Nov;30(11):1298-304. 
  16. Onishi Y, et al. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig 2013 Nov 27;4(6):605-12. 
  17. Gough SCL, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013 Sep;36(9):2536-42.
  18. Meneghini L, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013 Apr;36(4):858-64.
  19. Hollander P, et al. Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. Diabetes Obes Metab 2015 Feb;17(2):202-6.
  20. Wysham C, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA 2017 Jul 4;318(1):45-56. 
  21. Marso SP, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med 2017 Aug 24;377(8):723-732. 
  22. Heise T, et al. Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. Diabetes Ther. 2014 Jun;5(1):255-65.
  23. Skolnik N, et al. Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know. Clin Diabetes 2018 Apr;36(2):174-182.

Material desarrollado con fines de educación médica continua.

Material exclusivo para profesionales de la salud.

La información aquí presentada es opinión del ponente.

Código interno de aprobación: MX20XUM00048.

Leave a Reply

Close Menu